Holen Sie sich die Stockscreener-App
16.83
1.88%
0.39
Alto Neuroscience Inc Aktie (ANRO) Neueste Nachrichten
Alto Neuroscience completes enrollment in schizophrenia drug trial - Investing.com
Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia - Business Wire
Alto Neuroscience (NYSE:ANRO) Trading 9.8% HigherShould You Buy? - MarketBeat
Alto Neuroscience, Inc. (NYSE:ANRO) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Alto Neuroscience, Inc.'s (NYSE:ANRO) Intrinsic Value Is Potentially 58% Above Its Share Price - Yahoo Finance
Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment - BioSpace
Alto Neuroscience announces $75 million ATM offering - MSN
Aug Volume: Can Andretti Acquisition Corp. II Equity Warrant maintain its current growth rate2025 Breakouts & Breakdowns & Consistent Return Strategy Ideas - baoquankhu1.vn
Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire
Short Interest in Alto Neuroscience, Inc. (NYSE:ANRO) Drops By 21.0% - MarketBeat
Alto Neuroscience, Inc. (NYSE:ANRO) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Analyst Calls: What chart patterns are forming on VNOPRNTrade Signal Summary & Proven Capital Preservation Methods - baoquankhu1.vn
Alto Neuroscience receives patent for depression treatment method By Investing.com - Investing.com Nigeria
Alto Neuroscience issued patent for ALTO-207 - TipRanks
Alto Neuroscience Granted Patent for New Method of Treating Depression With ALTO-207 - marketscreener.com
Alto Neuroscience receives patent for depression treatment method - Investing.com
Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression - Business Wire
Short Squeeze: Can Alto Neuroscience Inc stock deliver strong Q4 earningsPortfolio Gains Summary & Reliable Price Breakout Signals - Bộ Nội Vụ
Alto Neuroscience, Inc. Presents New Data At the 64Th Annual Meeting of the American College of Neuropsychopharmacology - marketscreener.com
Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology - Business Wire
Chart Watch: Will Alto Neuroscience Inc stock test record highs in 2025Weekly Trade Review & AI Optimized Trade Strategies - Bộ Nội Vụ
Alto Neuroscience (NYSE:ANRO) Trading Up 8.1% – Should You Buy? - Defense World
Does Alto Neuroscience Inc. stock trade at a discount to peers2025 Retail Activity & Step-by-Step Trade Execution Guides - Улправда
What margin trends mean for Alto Neuroscience Inc. stockDividend Hike & Trade Opportunity Analysis - Улправда
Alto Neuroscience (NYSE:ANRO) Stock Price Up 8.1%What's Next? - MarketBeat
Why Alto Neuroscience Inc. stock could be next big winner2025 Breakouts & Breakdowns & High Accuracy Trade Signal Alerts - Улправда
How Alto Neuroscience Inc. stock performs in stagflationSell Signal & Consistent Profit Trading Strategies - Улправда
Is Alto Neuroscience Inc. stock bottoming after sell offWeekly Market Report & Consistent Income Trade Ideas - Улправда
Is Alto Neuroscience Inc. stock a good choice for value investorsPortfolio Diversification Tips & Low Cost Capital Gains - ulpravda.ru
Stifel Keeps Buy Rating on Alto Neuroscience (ANRO) - MSN
Is Alto Neuroscience Inc. stock supported by strong fundamentals2026 world cup usa national team qualification young talents high defensive line group prediction guide - ulpravda.ru
Chardan Capital Markets assumes coverage on Alto Neuroscience stock with Buy rating - Investing.com Canada
Chardan Capital Doubles Price Target for ANRO to $30 and Maintai - GuruFocus
Chardan Capital Raises Alto Neuroscience (NYSE:ANRO) Price Target to $30.00 - MarketBeat
Alto Neuroscience (NYSE:ANRO) Trading Down 6% – Here’s Why - Defense World
Alto Neuroscience (NYSE:ANRO) Shares Down 6%What's Next? - MarketBeat
Alto Neuroscience, Inc.'s (NYSE:ANRO) Institutional Investors Lost 10% Over the Past Week but Have Profited From Longer-term Gains - 富途牛牛
Alto Neuroscience (NYSE:ANRO) Stock Price Down 5.6%Here's Why - MarketBeat
Alto Neuroscience, Inc. (NYSE:ANRO) is definitely on the radar of institutional investors who own 33% of the company - Yahoo Finance
Alto Neuroscience Stock 9-Day Winning Spree: Stock Climbs 51% - Trefis
Will Alto Neuroscience Inc. stock continue upward momentumJuly 2025 Outlook & Fast Moving Stock Trade Plans - Улправда
Alto Neuroscience, Inc. (NYSE:ANRO) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Volume Summary: What sentiment indicators say about Alto Neuroscience Inc stockJuly 2025 Update & Accurate Trade Setup Notifications - moha.gov.vn
Is Alto Neuroscience Inc. stock safe for conservative investors2025 Institutional Moves & AI Forecast for Swing Trade Picks - Улправда
Alto Neuroscience Stock Rockets 51% With 8-Day Winning Streak - Trefis
How Alto Neuroscience Inc. stock benefits from global expansion2025 Biggest Moves & Verified Momentum Stock Watchlist - DonanımHaber
Will Alto Neuroscience Inc. stock sustain uptrend momentum2025 Winners & Losers & Daily Stock Trend Watchlist - DonanımHaber
Stock Analysis: Is Alto Neuroscience Inc. stock a good choice for value investors2025 Price Targets & Daily Volume Surge Trade Alerts - Улправда
0.66%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):